Hongbin Xu

Hongbin Xu is a Principal Scientist at Frontera Therapeutics, specializing in assay development, validation, and bioanalysis since January 2022. Prior experience includes roles as a Senior Scientist, Scientific Investigator, and Research Associate at various institutions, focusing on pharmacology studies, bioanalytic assay development for AAV gene therapy, and preclinical studies for ocular diseases. Hongbin's expertise encompasses a range of techniques, including q-PCR, dd-PCR, ELISA, and various immunoassays. Educationally, Hongbin holds a PhD in Molecular Microbiology from Huazhong Agricultural University and a Bachelor's degree in Biotechnology from the same institution.